Paratek Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

Global Markets Direct, December 2010, Pages: 37

Paratek Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Paratek Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Paratek Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Paratek Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Paratek Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Paratek Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Paratek Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Paratek Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Paratek Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Paratek Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Paratek Pharmaceuticals, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
Paratek Pharmaceuticals, Inc. Snapshot
Paratek Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Paratek Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Paratek Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Paratek Pharmaceuticals, Inc. – Pipeline Products Glance
Paratek Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Paratek Pharmaceuticals, Inc. – Drug Profiles
Tetracyclines for Asthma
Product Description
Mechanism of Action
R&D Progress
Tetracyclines for MS
Product Description
Mechanism of Action
R&D Progress
Tetracyclines for Rheumatoid Arthritis
Product Description
Mechanism of Action
R&D Progress
MAR Program
Product Description
Mechanism of Action
R&D Progress
Tetracyclines for SMA
Product Description
Mechanism of Action
R&D Progress
Tetracyclines for Stroke
Product Description
Mechanism of Action
R&D Progress
Tetracyclins For Clostridium
Product Description
Mechanism of Action
R&D Progress
Paratek Pharmaceuticals, Inc. – Pipeline Analysis
Paratek Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Paratek Pharmaceuticals, Inc. Pipeline Products By Target
Paratek Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Paratek Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Paratek Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Oct 27, 2004: Paratek Pharmaceuticals Presents Multiple Sclerosis Data At Society For Neuroscience Annual Meeting
Oct 27, 2004: Serono And Paratek Pharmaceuticals In Partnership To Develop A Novel Oral Treatment For Multiple Sclerosis
Financial Deals Landscape
Paratek Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2010
Paratek Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2010
Paratek Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2010
Paratek Pharmaceuticals, Inc. Detailed Deal Summary
Serono Enters Into An Agreement With Paratek Pharmaceuticals
Merck Enters Into Agreement With Paratek Pharmaceuticals
Paratek Pharmaceuticals Enters Into Co-Development With Medicines for Malaria Venture
Licensing Agreements
Paratek Pharmaceuticals Enters Into Licensing Agreement With Novartis
Warner Chilcott Enters Into Licensing Agreement With Paratek Pharmaceuticals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• eLEARNING - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Aerospace and Defense Industry - Global Strategic Business Report
• Charter Schools - Global Outlook
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles
• Defense Robotics - Global Strategic Business Report
• Aerospace and Defence Industry - Global Strategic Business Report